Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8013079 | 0.98 | HSP90AA1 (0.60) | HSP90AA1FAAHCASP2MEN1KMT2A | |
| SCHEMBL31520297 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL5932679 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL31168145 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL6684216 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL1803511 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL10481745 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL19359738 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL7769117 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL31607656 | 0.95 | HSP90AA1 (0.70) | HSP90AA1FAAHMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665348-A1 | COMPOSITIONS COMPRISING IBOGAINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-24 | — | — | EP | claimed |
| EP-4665327-A1 | COMPOSITIONS COMPRISING 3,4-METHYLENEDIOXYMETHAMPHETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-24 | — | — | EP | claimed |
| EP-4665317-A1 | COMPOSITIONS COMPRISING KETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-24 | — | — | EP | claimed |
| EP-4661877-A1 | COMPOSITIONS COMPRISING PSILOCYBIN, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES AND USES THEREOF | Clearmind Labs Corp. (CA) | 2025-12-17 | — | — | EP | claimed |
| US-20250302773-A1 | COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF | Clearmind Medicine Inc. (CA) | 2025-10-02 | — | — | US | claimed |
| WO-2025022362-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSKINESIA | Clearmind Medicine Inc. (IL) | 2025-01-30 | — | — | WO | claimed |
| WO-2024171075-A1 | COMPOSITIONS COMPRISING IBOGAINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Medicine Inc. (IL) | 2024-08-22 | — | — | WO | claimed |
| WO-2024171073-A1 | COMPOSITIONS COMPRISING 3,4-METHYLENEDIOXYMETHAMPHETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Medicine Inc. (IL) | 2024-08-22 | — | — | WO | claimed |
| WO-2024171074-A1 | COMPOSITIONS COMPRISING KETAMINE, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES, AND USES THEREOF | Clearmind Medicine Inc. (IL) | 2024-08-22 | — | — | WO | claimed |
| WO-2024166058-A1 | COMPOSITIONS COMPRISING PSILOCYBIN, OPTIONALLY IN COMBINATION WITH N-ACYLETHANOLAMINES AND USES THEREOF | Clearmind Medicine Inc. (IL) | 2024-08-15 | — | — | WO | claimed |
| WO-2019145783-A1 | COMPOSITIONS AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA | Therapix Biosciences Ltd. (IL) | 2019-08-01 | — | — | WO | claimed |
| US-20190183914-A1 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS | Therapix Biosciences Ltd. (IL) | 2019-06-20 | — | — | US | claimed |
| EP-3484469-A1 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS | Therapix Biosciences Ltd (IL) | 2019-05-22 | — | — | EP | claimed |
| US-20180116982-A1 | COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2018-05-03 | — | — | US | claimed |
| EP-3297622-A1 | COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd (IL) | 2018-03-28 | — | — | EP | claimed |
| US-20180078523-A1 | COMBINATION OF CANNABINOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2018-03-22 | — | — | US | claimed |
| EP-3288553-A1 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd (IL) | 2018-03-07 | — | — | EP | claimed |
| WO-2018011813-A1 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS | Therapix Biosciences Ltd. (IL) | 2018-01-18 | — | — | WO | claimed |
| WO-2016185468-A1 | COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2016-11-24 | — | — | WO | claimed |
| WO-2016174661-A1 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | Therapix Biosciences Ltd. (IL) | 2016-11-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302773-A1 | COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF | SLC18A2, PNMT, DBI | HSP90AA1 4651/4885FAAH 83/4885CASP2 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.